Lumora Announces Joint Development and Licensing Agreement with 3M for its Innovative BART Technology
News Sep 01, 2011
Lumora Ltd and 3M have signed a Joint Development and Licensing Agreement.
A recognized leader in research and development, 3M produces thousands of innovative products for diverse markets such as display & graphics, electronics & communications, manufacturing & industry, safety & security, office supplies, health care and home & leisure industries.
Conclusion of the Agreement enables 3M to develop and sell nucleic acid test kits utilizing Lumora’s BART technology.
Lumora specializes in the development of robust, affordable and easy-to use molecular diagnostics systems based on its proprietary 'BART' technology.
The company was founded in 2002 as a spin-out from the Institute of Biotechnology at the University of Cambridge, and now employs 13 people with a wide range of experience and operates from a dedicated, 6,100 sq ft facility.
The scientific team of nine includes four senior post-docs as well as IVD industry experienced process development staff.
Capabilities include bioinformatics, primer design, test optimization, test evaluation, protocol optimization, reagent stabilization and scale-up guidance. Lumora has microbiology experts in-house and facilities to deal with many common pathogens.
Lumora is seeking further collaborative development and licensing partnerships to bring its core technology to market in industrial sectors and clinical in vitro diagnostic applications.
For parties interested in learning more about opportunities to license BART for molecular diagnostics, Lumora will be presenting on future applications of the technology at two forthcoming conferences:
1. Dr Laurence Tisi, CEO, will speak on the digital applications of BART, at the Quality Control for Molecular Diagnostics (QCMD) conference in Glasgow, Scotland during September 2011
2. Paul Weinberger, CMO, will present opportunities for BART in clinical diagnostics at the AdvaMed 2011 MedTech conference in Washington during September 2011
When the Human Genome Project was completed, in 2003, it opened the door to a radical new idea of health - that of personalized medicine, in which disease risk and appropriate treatment would be gleaned from one's genetic makeup. In a new article, researchers discuss how gene interaction networks hold the clues to disease susceptibility and treatment response.READ MORE
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE